Curtis Tyree

Corporate Officer/Principal bei ORGANOVO HOLDINGS, INC.

Health Technology

Profil

Curtis Tyree is currently the Senior VP-Strategy & Business Development at Organovo Holdings, Inc. He previously worked as the Senior Vice President-Strategic Planning at HUYA Bioscience International LLC.

Aktive Positionen von Curtis Tyree

Unternehmen	Position	Beginn
ORGANOVO HOLDINGS, INC.	Corporate Officer/Principal	18.02.2022

Alle aktiven Positionen von Curtis Tyree

Ehemalige bekannte Positionen von Curtis Tyree

Unternehmen	Position	Ende
HUYA Bioscience International LLC HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA.	Corporate Officer/Principal	-

Sehen Sie sich die Erfahrung von Curtis Tyree im Detail an

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Curtis Tyree im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Börsennotierte Unternehmen	1
ORGANOVO HOLDINGS, INC.	Health Technology

Private Unternehmen	1
HUYA Bioscience International LLC HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA.	Health Technology